Inactive Instrument

American CryoStem Corporation

Equities

CRYO

US0253001046

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 03:04:01 2024-04-08 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	0.00%

2022	American CryoStem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	CI
2022	American CryoStem Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	CI

American Cryostem Corporation Reports Earnings Results for the Full Year Ended September 30, 2020

January 08, 2021 at 04:02 pm EST

American CryoStem Corporation announced earnings results for the full year ended September 30, 2020. For the full year, the company announced total revenue was USD 557,903 compared to USD 321,647 a year ago. Operating loss was USD 900,536 compared to USD 951,035 a year ago. Net loss was USD 1.179 million compared to USD 1.082 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.

Latest news about American CryoStem Corporation

American CryoStem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-22	CI
American CryoStem Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-05-23	CI
American CryoStem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2021	22-02-22	CI
American CryoStem Corporation Reports Earnings Results for the Full Year Ended September 30, 2021	22-01-13	CI
American CryoStem Corporation Auditor Raises 'Going Concern' Doubt	22-01-12	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-23	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-05-17	CI
American Cryostem Corporation Reports Earnings Results for the Full Year Ended September 30, 2020	21-01-08	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2020	20-08-19	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2020	20-05-20	CI
American Cryostem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2019	20-02-19	CI
American Cryostem Corporation Reports Earnings Results for the Full Year Ended September 30, 2019	20-01-14	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter Ended June 30, 2019	19-08-19	CI
American Cryostem Corporation Reports Earnings Results for the Second Quarter Ended March 31, 2019	19-05-20	CI
American CryoStem Corporation Completes Cooperative Framework Agreement to Expand Market Presence in Japan	19-03-20	CI
American Cryostem Corporation Reports Earnings Results for the First Quarter Ended December 31, 2018	19-02-19	CI
American CryoStem Corporation Enters into Agreement to License its Patented Adipose Tissue and Stem Cell Technologies in Thailand	18-04-05	CI
American CryoStem Corporation Secures Major Contract in Mainland China	17-09-25	CI
American Cryostem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2017	17-08-22	CI
American Cryostem Corporation Reports Revenue Results for the Year Ended September 30, 2016	17-01-03	CI
American CryoStem Corporation Expands with the Opening of New Lab Facility in Princeton, NJ	16-04-06	CI
American Cryostem Corporation Auditor Raises 'Going Concern' Doubt	16-01-12	CI
American Cryostem Corporation Signs Licensing Agreement with Cell Source	15-07-22	CI
American Cryostem Corporation acquired certain assets of BioLife Cell Bank, Inc.	15-04-20	CI
American Cryostem Corporation Auditor Raises 'Going Concern' Doubt	15-01-19	CI

Chart American CryoStem Corporation

Duration

Period

More charts

Company Profile

American CryoStem Corporation is a biotechnology company. The Company has developed adipose tissue-derived technologies (Adult Stem Cells) for the fields of regenerative and personalized medicine. Its technologies are the basis for the chemistry, manufacturing, and controls (cGMP Manufacturing) of its ATCell autologous cellular therapy product for use in clinical investigations for biologic license applications with the United States Food and Drug Administration (FDA). The Company has developed and refined its pipeline around its cellular product, ATCell, for clinical therapeutic use. The Companyâs ATCELL cell lines are cultured in its patented ACSelerate cell culture media. Its CELLECT service is the required platform for the collection and transportation of live adipose tissue samples to its processing facility. Its ACSelerate cell culture media products are manufactured using patented cell culture media for growing human stromal cells. The Company also includes ATGRAFT services.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research